ProMIS Neurosciences to Participate in Several Key Conferences in September
CAMBRIDGE, Mass, Sept. 01, 2026 /CourierPR/ -- ProMIS Neurosciences, a clinical-stage biotechnology company based in Cambridge, Massachusetts and Toronto, Ontario, is set to participate in several high-profile conferences and events in September 2026. The company's leadership, including CEO Neil Warma, Chief Medical Officer Dr. Larry Altstiel, and Vice President of Investor Relations and External Affairs Carie Pierce, will discuss the company's innovative EpiSelect™ platform and lead candidate PMN310 during these gatherings.
On September 9-11, ProMIS will attend the Cantor Global Healthcare Conference in New York City. Dr. Altstiel and Mr. Warma will participate in a fireside chat on Wednesday, September 9, from 9:10 to 9:40 a.m. Eastern Time. The conference will feature a webcast available at a provided link.
From September 9-10, the company will also participate in the Moody Capital Disruptive Growth & Life Sciences Conference. Mr. Warma, Dr. Altstiel, and Ms. Pierce will deliver a presentation on Thursday, September 10, from 1:45 to 2:05 p.m. Eastern Time, in Room 1. The presentation will be webcast live and can be viewed via a provided link.
On September 14-16, ProMIS Neurosciences will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is scheduled for Tuesday, September 15, from 10:30 to 11:00 a.m. Eastern Time in the Louis Room on the fourth floor. Webcast details for this event are also available.
Additionally, ProMIS will commemorate World Alzheimer’s Day on September 21 by marking the occasion at the Nasdaq Tower in New York City.
During these conferences, the company will highlight its EpiSelect™ platform, which it describes as a differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins. PMN310, the company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial for early Alzheimer’s disease, will be a key focus.
ProMIS recently reported interim blinded 6-month data from its fully enrolled PRECISE-AD Phase 1b trial, with 12-month topline data expected in early 2027. Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available on the company’s website.
ProMIS Neurosciences aims to leverage these events to advance its mission of discovering and developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative and other misfolded protein diseases.